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ARTICLE
Landscape of multi-nucleotide variants in 125,748
human exomes and 15,708 genomes
Qingbo Wang 1,2,3, Emma Pierce-Hoffman1, Beryl B. Cummings1,2,4, Jessica Alföldi 1,2,
Laurent C. Francioli 1,2, Laura D. Gauthier1,5, Andrew J. Hill1,6, Anne H. O’Donnell-Luria 1,2,
Genome Aggregation Database Production Team, Genome Aggregation Database Consortium,
Konrad J. Karczewski 1,2 & Daniel G. MacArthur 1,2,7,8*
Multi-nucleotide variants (MNVs), defined as two or more nearby variants existing on the
same haplotype in an individual, are a clinically and biologically important class of genetic
variation. However, existing tools typically do not accurately classify MNVs, and under-
standing of their mutational origins remains limited. Here, we systematically survey MNVs in
125,748 whole exomes and 15,708 whole genomes from the Genome Aggregation Database
(gnomAD). We identify 1,792,248 MNVs across the genome with constituent variants falling
within 2 bp distance of one another, including 18,756 variants with a novel combined effect on
protein sequence. Finally, we estimate the relative impact of known mutational mechanisms -
CpG deamination, replication error by polymerase zeta, and polymerase slippage at repeat
junctions - on the generation of MNVs. Our results demonstrate the value of haplotype-
aware variant annotation, and refine our understanding of genome-wide mutational
mechanisms of MNVs.
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Multi-nucleotide variants (MNVs) are defined as clustersof two or more nearby variants existing on the samehaplotype in an individual1,2 (Fig. 1a). When variants in
an MNV are found within the same codon, the overall impact
may differ from the functional consequences of the individual
variants3. For instance, the two variants depicted in Fig. 1b are
each predicted individually to have missense consequences, but in
combination result in a nonsense variant. Such cases, which
would be missed by virtually all existing tools for clinical variant
annotation, can result both in missed diagnoses and false positive
pathogenic candidates in analyses of families affected by genetic
diseases1,2.
MNV identification tools4–8 have been applied to databases of
human genetic variation at varying scales, including 1000 Gen-
omes9 Phase 3 (2504 individuals with high coverage exome and
low coverage genome-sequencing data), and the Exome Aggre-
gation Consortium1 (60,706 individuals with high coverage
exome data). Together, these analyses identified over 10,000
MNVs altering protein sequences, demonstrating the pervasive
nature of MNV annotation in the population-level data. In
addition, analysis of the 1000 Genomes data set highlighted dif-
ferences in the frequencies of MNVs depending on sequence
context10. In combination with yeast experiments11–13, biological
mechanisms that account for the enrichment of specific types of
MNVs, such as DNA replication error by polymerase zeta, have
been suggested.
Studies of newly occurring (de novo) MNVs have also been
performed using trio data sets2,14–16; analysis of 283 trios with
whole-genome sequence data16 confirmed that MNV events
occur much more frequently than expected by random chance. By
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focusing on noncoding regions, this study also highlighted
potentially different mechanisms that dominate MNV generation
depending on the genomic region and the distance between the
two constitutive variants. As part of the Deciphering Develop-
mental Disorders (DDD) study17, Kaplanis et al.2 analyzed
exome-sequence data from over 6000 trios to quantify the
pathogenic impact of MNVs in developmental disorders, showing
that such variants are substantially more likely to be deleterious
than SNVs and further clarifying the mutational mechanisms that
generate them. These analyses also have provided estimates of the
germline MNV rate per generation, falling into a consistent range
of 1–3% of the SNV rate. Although these studies have provided
valuable information about the mutational origins and functional
impact of MNVs, to date there has been no analysis that inves-
tigated MNVs across the entire genome (including noncoding
regions) in many thousands of deeply sequenced individuals,
limiting our understanding of the genome-wide profile and
complete frequency distribution of this class of variation.
Here, we present the analysis of a large-scale collection of
MNVs, along with clinical interpretation of MNVs from
over 6000 sequenced individuals from rare disease families.
We also provide gene-level statistics on MNVs and describe the
distribution of MNVs by functional consequence and by
gene-level constraint. Finally, to enhance our understanding of
MNV mechanisms, we examine the distributions of MNVs
stratified by more than ten different functional annotations
across the human genome, as well as estimates of the genome-
wide per-base frequencies of the dominant mutational processes
generating MNVs.
Results
Read-based phasing for identification of MNVs. Identification
of MNVs requires the constituent variants to be properly phased
—that is, to be identified accurately as either both occurring on
the same haplotype (in cis) or on two different haplotypes (in
trans). Phasing can be performed following three broad strategies:
read-based phasing18, which assesses whether nearby variants co-
segregate on the same reads in DNA sequencing data; family-
based phasing19, which assesses whether pairs of variants are co-
inherited within families; and population-based phasing20, which
leverages haplotype sharing between members of a large geno-
typed population to make a statistical inference of phase. Read-
based phasing is particularly effective for pairs of nearby variants,
making it suitable for the analysis of MNVs.
For this project, we generated read-based phasing results for
variants in the Genome Aggregation Database (gnomAD) v2.1
callset using GATK HaplotypeCaller21, yielding 125,748 human
whole exomes and 15,708 genomes with local phase information;
the properties of this callset are described in detail in an
accompanying paper22. To assess phasing accuracy, we used 5785
family trios with exome-sequencing data and 635 family trios
with whole-genome sequencing data that largely overlapped with
the gnomAD 2.1 release data. We calculated the phasing
sensitivity, defined as the fraction of heterozygous variant pairs
that have read-based phase information assigned for both
variants, and found that it was 87.9% for adjacent heterozygous
variant pairs, reflecting the stringent haplotype-calling criteria of
GATK21 (Supplementary Tables 1–3). We used Phase-By-
Transmission (PBT)19, a family-based phasing method (Fig. 1c),
to assess our phasing specificity, and found that over 99.8% of the
MNVs identified with read-based phasing were consistent with
the PBT trio-based phasing. The sensitivity and specificity of our
read-based phasing remained high even when the two variants of
the MNV were 10 bp apart (82.8% and 99.8%; Supplementary
Fig. 1 and Supplementary Table 1). These results demonstrate
high specificity and sensitivity for the detection of MNV events
across the genome.
Functional impact of MNVs. In order to provide an overview of
the functional impact of MNVs (Fig. 1b), we examined all phased
high-quality SNV pairs (i.e., SNV pairs that pass stringent fil-
tering criteria; see the Methods section) within 2 bp distance of
each other across the 125,748 exome-sequenced individuals from
our gnomAD 2.1 data set, resulting in the discovery of 31,575
MNVs exist within the same codon. When the two variants
comprising the MNV were considered together, the resulting
functional impact on the protein differed from the independent
impacts of the individual variants in ~60% of cases (18,756
MNVs; Fig. 2a; Supplementary Data 1). Among the differing
annotations of functional consequence, 407 were gained nonsense
(neither individual SNV was a nonsense mutation, but the
resulting MNV is), and 1821 were rescued nonsense (at least one
of the two individual SNVs would create a nonsense mutation,
but the resulting MNV does not). Such categories of MNVs have
a major impact on variant interpretation, and thus are critical for
accurate variant annotation. There was an average of 55.2 variants
with altered functional interpretation (including 0.062 gained and
4.42 rescued nonsense) due to MNVs per individual.
To understand the overall impact of correctly annotating the
functional consequence of MNVs in a population-level data set,
we counted the number of gained/rescued nonsense mutations
per gene in gnomAD (Fig. 2b; Supplementary Data 1). For
rescued nonsense mutations, we found 1538 sites that are rescued
in all the individuals with the component variants. A total of 1633
genes carried gained or rescued nonsense mutations within our
data set, including 41 genes that are disease-relevant (reported by
OMIM23 or annotated as haploinsufficient by Clingen24,25). In
addition, the proportion of rescued nonsense mutations of falling
in predicted loss-of-function (pLoF) constrained genes (genes
with a significant depletion of pLoFs compared with an
expectation based on a mutational model1,26, defined as LOEUF22
decile <20%) was higher (proportion= 0.219) when compared
with all the other classes of MNVs (proportion= 0.192; Fisher’s
exact test, p= 0.0247; Fig. 2c; Supplementary Fig. 2). Conversely,
gained nonsense mutations are depleted among constrained genes
(proportion= 0.0620) compared with all other classes of MNVs
(Fisher’s exact test, p= 1.01 × 10−11). These results suggest a
significant enrichment of LoF annotation errors in the absence of
MNV annotation.
In addition, we have investigated another class of variant pairs
whose combined interpretation can be highly different from
either of the individual component variants: insertion/deletion
(indel) pairs that result in frame restoration (e.g., 4 bp deletion+
7 bp insertion, resulting in 3 bp= 1 amino acid insertion), and
have annotated such frame-restoring indel pairs (n= 1406) when
separate by up to 30 bp (considering the limitations of read-based
phasing; Supplementary Fig. 3). When we compare the LoF
confidence of constituent indels, we found that the proportion of
frame-restoring indel pairs falling on LoF-constrained genes were
significantly higher when the constituent indels are high-
confidence (HC) LoFs (proportion= 0.0262 for low-confidence,
LC, and 0.167 for HC pairs. Fisher’s exact test, p= 1.66 × 10−7;
Supplementary Fig. 3h), suggesting that frame-restoring indel
pairs can also be a source of LoF annotation errors.
Finally, in order to understand the impact of these variants in
clinical applications, we also annotated MNVs in 6072 sequenced
individuals from rare disease families, including 4275 case
samples. This resulted in 16 gained nonsense mutations and
110 changed missense MNVs with high CADD27 scores and low
frequencies in gnomAD (CADD >20 and <10 individuals in
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gnomAD; Supplementary Data 2). However, after close manual
curation, none of the corresponding MNVs were definitively
causal variants for the diseases affecting the family, suggesting
that MNVs contribute to only a small fraction of total rare disease
diagnoses, in line with expectations based on their relative rarity
and previous results2.
Genome-wide mutational mechanisms of MNVs. We next
turned our attention to understanding the mutational mechan-
isms underlying the origins of MNVs genome-wide, focusing on
whole-genome sequence data from 15,708 individuals in the
gnomAD v2.1 callset. We considered pairs of high-quality var-
iants in autosomes separated by up to 10 bp, resulting in the
assembly of a catalogue of 5,513,219 MNVs including 1,792,248
MNVs within 2 bp distance—an order-of-magnitude increase in
size over previous collections.
We considered three established major categories of mutational
origins of MNVs with constituent SNVs falling next to each other
(adjacent MNVs. Figure 3a), each of which is biased toward
certain MNV patterns: (1) combinations of distinct single-
nucleotide mutation events; (2) replication errors by error-
prone polymerase zeta; and (3) polymerase slippage events at
repeat junctions. MNVs in the first category are a product of two
or more SNVs, which typically occur in different generations and
may thus have different allele frequencies. We expect to see an
enrichment of CpG transition compared with non-CpG transver-
sion for this class, due to the underlying difference of SNV
mutation rate28–30. The second category, replication error
introduced by DNA polymerase zeta (pol-zeta), is a well known
class of replication error that introduces MNVs. Previous
studies10–13,31 have shown that pol-zeta is prone to specific types
of replication error, mainly TC- > AA, GC- > AA, and their
reverse complements, with experimental evidence that these
MNV patterns occur in a single generation; thus, the constituent
SNVs will typically have the same allele frequencies. The third
category, replication slippage, is another known mode of DNA
replication error32–34. This process is especially frequent at sites
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with repetitive sequence context; previous studies35–37 have
shown that the indel rate can be up to 106 times higher than
the SNV mutation rate at these sites. As shown in Fig. 3a, the
combination of an insertion and then a deletion of two base pairs
can result in an MNV.
We observed the signature of each of these MNV mechanisms
in our data set. First, we calculated the number of MNVs for each
MNV pattern (Fig. 3b) and observed that the most frequent MNV
pattern is CA- > TG substitutions, which are likely to occur as a
combination of an A- > G transition, followed by a high mutation
rate C- > T CpG transition (Supplementary Fig. 4a). On the other
hand, the least frequent MNV pattern is TA- > GC substitutions,
which occur as a combination of two non-CpG transversions. The
273.4-fold difference (270,071 versus 988) of the frequency of
MNVs between these two patterns is comparable with the
theoretical ratio calculated based on the mutation rate of the
component SNVs (475.6-fold), and the overall correlation
between the theoretical and observed frequency of each MNV
pattern was strong (Pearson correlation r= 0.839 with p= 9.15 ×
10−22 in log space; Supplementary Fig. 4b–e).
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To investigate the extent of pol-zeta signature, we calculated
the number of MNVs in which the gnomAD allele counts of the
constitutive single-nucleotide variants are equal (following
previous methodology2, also described in the Methods section),
and observed that these one-step MNVs are significantly enriched
in MNV patterns matching the pol-zeta signature (90.5% for GA-
> TT, and 80.5% for GC- > AA, compared with 39.9% overall;
Fisher’s exact test, p < 10−100; Fig. 3c).
Finally, in order to capture polymerase slippage events, we
calculated the fraction of MNVs in repetitive contexts per MNV
pattern (Fig. 3d). For the MNV patterns AA- > TT, >30% of all
the MNVs observed were in repetitive contexts. The fractions of
the MNV patterns AT- > TA and TA- > AT in repetitive contexts
were also high, exceeding 10% (Fisher’s exact test, p < 10−100
compared with the 3.15% across all patterns). For all MNV
patterns in repeat contexts, we see a significant excess of MNVs
compared with the expected number based on a model that
assumes MNVs are simple combination of two SNV events
(Supplementary Fig. 4). These observations support the role of
replication slippage as one of the major drivers of MNVs. In
addition, we did not see a correlation between the frequency of
one-step MNVs and the frequency of MNVs in repetitive contexts
(Pearson correlation r= 0.0561, p > 0.05; The fraction of one-step
MNVs exceeded 80% for AT- > TA and TA- > AT, but was 46%
for AA- > TT), suggesting that multiple slippage events leading to
MNV generation can take place either as a single event (i.e., in
single generation) or multiple events (i.e., in different generation),
or even recurrently. These findings come with the caveat that
variants in repetitive regions will have higher error rates due to
slippage and misalignment errors, but we have reduced this risk
by applying random forest filtering for individual sites, as well as
removing all the variants in low-complexity regions from our
analysis (see the Methods section).
Estimation of global mutation rate of MNVs. In order to
compare the frequency of three different mechanisms, we
quantified the contribution of two single-nucleotide variation
events vs other replication error modes, such as pol-zeta errors
or replication slippage, using a simple probabilistic model.
Specifically, focusing on adjacent MNVs, we assigned the MNV
frequency for each MNV pattern to be the sum of the prob-
ability of two SNV events (P) and the probability of other
replication error factors (Q), and estimated the Q term. In other
words, we estimated the divergence of the observed number of
MNV sites from the number expected by a simple SNV
mutation model (see the Methods section). The resulting esti-
mated proportion of two SNV events and other replication
error events is described in Fig. 4a.
As expected, the proportion differs substantially from one
MNV pattern to another. For example, while 98.0% of CA- > TG
MNVs appear to be caused by combinations of simple SNV
events, the corresponding proportion is 5.84% for GA- > TT,
18.9% for GC- > AA, and 9.52% for AA- > TT MNVs. We
presume that the lower proportion of two simple SNV events is
mainly due to pol-zeta errors for GA- > TT and GC- > AA, and
polymerase slippage for the AA- > TT. Since 83.2% of the overall
MNVs were classified as either SNV combination, repeat context,
or pol-zeta error at GA- > TT or GC- > AA, our analysis suggests
that these three major categories explain a substantial fraction of
MNV events genome wide, although some possible additional
mechanisms with smaller frequencies might exist. These calcula-
tions also allow us to estimate the genome-wide mutation rate of
MNVs caused by pol-zeta: 1.59 × 10−10 per 2 bp per generation
for GA- > TT, and 4.08 × 10−10 for GC- > AA. Given that there
are ~1.66 × 108 GA pairs and 1.20 × 108 GC pairs in the reference
human genome, we estimate there are on average 0.026 GA- > TT
and 0.049 GC- > AA mutations per generation (Supplementary
Data 3).
We also explored the potential mutational mechanisms for
MNVs with a greater distance between the component variants
(Supplementary Figs. 5–7), and observed signatures of non-
independence of mutation events extending over distances up to
10 bp, with an enrichment of motifs consistent with pol-zeta and
polymerase slippage mechanisms for adjacent MNVs (minimum
1.08, maximum 4.06-fold enrichment of one-step MNV, Fisher’s
exact test, p-value < 0.05; Supplementary Figs. 8,9). This confirms
the presence of mutational mechanisms capable of creating
simultaneous mutations separated by considerable
distances16,29,38–40, although further work will be required to
fully characterize the underlying processes.
Overall, our analysis of MNVs in 15,708 whole-genome-
sequenced individuals supports the previously suggested three
major mechanism of MNVs and quantifies the different
contribution of each mechanism for different MNV patterns at
the genome-wide scale.
MNV distribution across different genomic regions. We next
examined how MNV pattern distributions differ between func-
tional annotation categories. We used 13 different functional
annotations such as coding sequence, enhancer, and promoter
from Finucane et al.41, and the DNA methylation annotation
from the Encyclopedia of DNA Elements (ENCODE)42, to cal-
culate the number of MNVs that fall into each category (Sup-
plementary Table 4). MNV density, defined as the number of
MNVs observed in each functional category divided by the total
length of the genomic interval belonging to each category, is
shown in Fig. 4b and c. We found that MNV density of the
substitution patterns typically involving CpG transitions is posi-
tively correlated with the methylation level (linear regression
Pearson correlation r= 0.95 for CG- > TA and r= 0.87 for CA- >
TG, p < 10−3). Conversely, MNV density for non-CpG trans-
version-related substitution patterns, and the substitution pat-
terns related to pol-zeta slippage, negatively correlates with
methylation status (linear regression Pearson correlation r=
−0.90 for GA- > TC, r=−0.91 for AG- > CC, r=−0.91 for
GA- > TT, and r=−0.92 for GC- > AA, p <10−5; Fig. 4b, c).
Finally, we explored the effect of genic context on MNV origins
and discovery: we selected the seven major regional annotations
around gene-coding sequences43,44, and calculated the fraction of
MNVs likely explained by different mutational origins in each of
these regions (Fig. 4d). Across all regions, we found that the
MNV signal is primarily dominated by CpG transitions. The
fraction of non-CpG transversions and polymerase slippage at
repeats were consistently lower than (or nearly equal to) 5% of
the overall signal. Pol-zeta signature was not as dominant as CpG
transitions, except for at the transcription start site region, which
has by far the lowest methylation rate in those seven annotations,
and is thus expected to have a lower rate of CpG deamination
mutations (which are dependent on the methylation of the
original cytosine).
Overall, our results suggest that MNV density is highly
dependent on the CpG methylation status of the surrounding
sequence, and that MNVs that originate from non-CpG
transversions or polymerase slippage at repeat junctions are
relatively uncommon compared with those driven by CpG
transitions or pol-zeta errors. Finally, MNVs that originate
from pol-zeta error are the most common class of MNVs in the
region close to the transcription start sites of genes, as low
methylation levels in these regions result in low levels of CpG
transitions.
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Discussion
We analyzed 125,748 human exomes and 15,708 genomes and
identified 1,792,248 MNVs across genome with constituent var-
iants falling within 2 bp distance, including 31,575 that exist
within a codon. We have shown that MNVs represent an
important class of genetic variation, and that they have a sig-
nificant impact on the functional interpretation of genomic data,
both at the population and individual level. Although we did not
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encounter an individual in which an MNV is the likely cause of a
rare disease after sequencing 6072 individuals from rare disease
families, we expect that applying our pipeline to larger numbers
of disease samples will identify previously missed diagnoses, as
has been observed in another study of developmental delay
cases2.
The large number and high quality of variant calls in the
gnomAD database provided increased power for statistical ana-
lysis of the three major mutational mechanisms (combinations of
independent SNVs; replication errors by pol-zeta; and polymerase
slippage at repeat junctions) responsible for the generation of
MNVs, and importantly allowed us to estimate the relative con-
tribution of each of these processes.
Our estimates of substitution pattern-specific MNV mutation
rate and fraction come with important caveats. Our approach
assumes that the local SNV mutation rate is invariant across
instances of a specific 3 bp context; however, prior work has
shown considerable regional variation in mutation rate across the
genome, as well as variation driven by ancestry, environment, and
other factors45–48. Another important limitation is the lack of
confident estimates of insertion and deletion rate as a function of
repeat length, which limits the confidence of our estimate of the
fraction of polymerase slippage. Future large genome-scale data
sets with more accurate insertion and deletion calls, likely
involving long-read sequencing data, will be required to improve
modeling of insertion and deletion mutations.
One clear feature of our data set was the signature of non-
independence of mutational events separated by up to 10 bp, as
suggested in various de novo studies16,29,38–40; further investi-
gation of these clustered mutations, and contextualizing them
with known sources of genomic instability, such as homologous
recombination49 or transposable elements50,51, will be informa-
tive in exploring the mechanisms of clustered mutations.
The complete list of MNVs identified in gnomAD is publicly
available (https://gnomad.broadinstitute.org/downloads), with the
allele count annotated for both genome and exome. For the
coding regions, we have also annotated the functional con-
sequence of constituent SNVs and MNVs separately, and made
the result viewable in an intuitive browser (https://gnomad.
broadinstitute.org). Although some fraction of MNVs is missing
from this list due to incomplete phasing sensitivity and read
coverage, the database provides the most comprehensive set of
estimates of MNV allele frequencies to date, valuable for further
analysis of mutational mechanisms as well as the interpretation of
MNVs in rare disease and cancer genomics52,53.
Finally, despite the large sample size of our MNV data set, the
fraction of MNVs that we have observed out of all the possible
MNV configurations is still very far from saturating the space of
possible MNVs, with only ~0.005% of all possible adjacent MNVs
observed in our data (Supplementary Figs. 10, 11). Increasing the
number of sequenced individuals54 in both disease and non-
disease cohorts will permit the discovery and determination of the
phenotypic impact of an increasingly comprehensive catalogue of
variation. This study confirms the importance of incorporating
haplotypic phase into these efforts to permit the discovery and
accurate interpretation of the full range of human variation.
Methods
Ethics. We have complied with all relevant ethical regulations. This study was
overseen by the Broad Institute’s Office of Research Subject Protection and the
Partners Human Research Committee, and was given a determination of Not
Human Subjects Research. Informed consent was obtained from all participants.
MNV calling. 125,748 human exomes and 15,708 genomes from gnomAD 2.1
callset were used for the analyses (Supplementary Tables 5,6). We used hail
(https://github.com/hail-is/hail), an open source, cloud-based scalable analysis tool
for large genomic data. For MNV discovery, we exhaustively looked for variants
that appear in the same individual, in cis, and within 2 bp distance for the exome
data set and 10 bp distance for the genome data set, using the hail window_by_locus
function (i.e., we computationally checked every pair of genotypes within a certain
window size, for every individual, to see whether the individual carries a pair(s) of
mutation in the same haplotype. See Supplementary Methods for further detail.
Also, we did not expand the window size >10 bp for MNV discovery, as phasing
sensitivity significantly drops when the distance between variants is >10 bp, as
shown in Supplementary Fig. 1d). For trio-based analyses, we expanded the range
to 100 bp to obtain a more macroscopic view. Although we performed MNV
calling in sex chromosomes for the coding region, we restricted our analysis to
autosomes, in order to control for differences in zygosity.
MNV calling in rare disease samples was performed in a similar fashion as in
the gnomAD exome data set. In total, 6072 rare disease whole-exome sequences
were curated at the Broad Center for Mendelian Genomics (CMG)55 and went
through the MNV calling pipeline with the window size of 2 bp distance. The
phenotypes observed in the cohort include: muscle disease such as Limb Girdle
Muscular Dystrophy (LGMD; roughly one-third of the total), neurodevelopmental
disorders, or severe phenotypes in eye, kidney, cardiac, or other orphan diseases
(Supplementary Data 2).
MNV filtering. In the gnomAD MNV analysis, variant pairs for which one or both
of their components have low quality reads were filtered out. Specifically, we only
selected the variant sites that pass the Random Forest filtering, resulting in
acceptance of 53.3% of the initial MNV candidates (Supplementary Fig. 12a). We
also filtered out variant sites that are classified as low-complexity regions (LCRs)
identified with the symmetric DUST algorithm56 at a score threshold of 30, and
additionally applied adjusted threshold criteria (GQ ≥ 20, DP ≥ 10, and allele bal-
ance > 0.2 for heterozygote genotypes) for filtering individual variants (Supple-
mentary Table 7). For each MNV site, we annotated the number of alleles that
appear as MNV, as well as the number of individuals carrying the MNV as a
homozygous variant. The distribution of MNV sites that contain homozygous
MNVs is shown in Supplementary Fig. 13. We also collapsed the MNV patterns
that are reverse complements of each other, after observing that the number of
MNVs are roughly symmetric (before collapsing, the ratio of each MNV pattern to
its corresponding reverse complement pattern was mostly close to 1, with 0.95
being the lowest and 1.10 being the highest for adjacent MNVs) (Supplementary
Fig. 14). All the MNV patterns in the main text and figures are equivalent to their
reverse complement, and we do not distinguish them.
For the rare disease cohort, since our motivation was to find a definite example
where an MNV is acting as a causal variant for a rare disease with severe phenotype
rather than obtaining the population-level statistics, we did not apply site and
sample-specific filtering, as opposed to the gnomAD MNV analysis. Instead of
being computationally filtered by read quality, the 129 putative MNVs (16 gained
nonsense mutations, 110 changed missense with high CADD score and low
gnomAD MNV frequency, and 3 gained missense) went through manual
inspection by the analysts at the Center for Mendelian Genomics (CMG) at the
Broad Institute55, after annotating the affected gene. Specifically, all the variants
were checked manually under the criteria below:
- Whether the gene affected is constrained in the gnomAD population.
- Whether the case has already been solved with other causal variant.
- Whether the MNV looks real in the Interactive Genome Browser (IGV).57
- Whether the MNV is in the proband and, if applicable, the segregation pattern
of the MNV
- Whether the known function of the gene affected matches the patient
phenotype.
MNVs were filtered out if they failed one or more of the criteria above. These
results suggest that MNVs explain only a small fraction of undiagnosed genetic
disease cases, consistent with their overall frequency as a class of variation, and
with prior work in large disease-affected cohorts2. The summary for MNV analysis
in rare disease cohort is also available at Supplementary Data 2.
Analysis of phasing sensitivity. In order to compare the phasing information
derived from different methods (read-based and trio-based), we took an
approach of comparing the relative phase (binary classification of whether two
SNVs of MNV are in the same haplotype or not), as shown in Supplementary
Table 8. We investigated the heterozygous variant pairs whose phasing infor-
mation is not provided by the trio-based phasing and observed that majority
(83.5%) of the cases reflected both parents carrying a heterozygous variant, a
scenario where trio-based phasing is inherently uninformative. We also inves-
tigated the heterozygous variant pairs whose phasing information is not pro-
vided by the read-based phasing. Specifically, unphased pairs tend to have either
low- or high-read depth (odds ratio= 3.20, Fisher’s exact test, p < 10−100 for low,
and odds ratio= 2.33, Fisher’s exact test, p < 10−100 for high-read depth; Sup-
plementary Table 3), consistent with our previous understanding that an excess
of reads can lead to involvement of erroneous reads and thus reduce the con-
fidence of phasing of HaplotypeCaller58 (as well as the lack of the number of
reads reduces the calling rate). All the statistical tests are two-sided, throughout
the paper.
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Analysis of functional impact in coding region. We focused on the coding region
of the canonical transcript of genes and examined the codon change and their
consequence for all the MNVs that fall in a single codon (see Supplementary
Tables 9,10 for the number of MNVs that spans across two codons). When
comparing with population-level constraint, for each MNV, we annotated the
constraint metric (LOEUF22) of the gene whose protein product is affected. For
rescued nonsense mutations, we took only the ones are rescued in all the indivi-
duals with the component variants (i.e., we excluded the ones whose allele count of
MNVs are not equal to the allele count of the SNV that introduces a nonsense
mutation), resulting in 1538 out of 1821 rescued nonsense mutations. We next
used Loss-Of-Function Transcript Effect Estimator (LOFTEE22) in order to exclude
the nonsense mutations that are not likely to affect the protein function. This
resulted in 371 high-confidence (HC) gained nonsense mutations and 1400 HC
rescued nonsense mutations, which were used for the population-level constraint
analysis. In addition, we stratified the gene sets by core essential/nonessential genes
from CRISPR/Cas knockout experiments59,60 as an orthogonal indicator of gene
constraint (Supplementary Fig. 2).
We did not include and correct for MNVs consisting of three SNVs in a single
codon in the analysis of functional impact in coding region, since the number and
frequency of such MNVs are significantly low (228 in total, with 5 newly gained
nonsense, but no re-rescued or re-gained nonsense; 0.220 in total per person). The
full list of such MNVs are available as a separate file at: https://gnomad.
broadinstitute.org/downloads.
Frame-restoring indel analysis was performed in a similar fashion. We used the
gnomAD exome data set to call and filter the insertion/deletion pairs using the
same filtering criteria (except for the fact that we did not restrict our analysis to
cases where the frameshift effect would be rescued in all individuals), and focused
on the canonical transcripts for the functional impact evaluation.
Defining one-step MNVs and MNVs in repetitive contexts. A one-step MNV
was defined as a MNV for which the allele count of both SNVs that make up the
MNV is the same and close to the allele count of the MNV itself. We also compared
the allele count of constituent SNVs (AC1 and AC2) with the allele count of the
corresponding MNV (AC_mnv), and observed that the majority of one-step MNVs
we discovered have AC_mnv divided by AC1 >0.9 (Supplementary Fig. 15).
Therefore, we expect the false discovery rate of one-step MNVs (misclassifying the
MNV whose AC1 and AC2 are equal just by chance) to be limited. The full
distribution of all the allele counts, including per-population characterizations, are
shown in Supplementary Fig. 16 and Supplementary Table 11.
Repetitive sequences are defined by taking the ±4 bp context of the MNV and
setting the threshold manually, by looking at the distribution of repeat contexts
around all the MNVs (Supplementary Figs. 17, 18). Specifically, a sequence is
defined as repetitive if the number of dinucleotide repeat units > 1, for both
reference and alternative ±4 bp context, and the number of dinucleotide repeat
units > 2, for either reference or alternative ±4 bp context, and, for adjacent MNVs
only, if the reference and/or alternative 2 bp are mononucleotide repeat, increase
the threshold by one mononucleotide repeat unit.
Here, dinucleotide repeat unit is defined as the reference or the alternative allele
itself (with the gap when d > 1 and counting the overlap. For example, the reference
and alternative dinucleotide repeat counts for TATATAT - > TAAAAAT are both
3). The third criteria was added specifically for adjacent MNVs to adjust for
counting the overlap more than once. This threshold was set so that the number of
MNVs with equal or higher repeats would be <5% of the total, corresponding to
two standard deviations away from the mean, and also because the estimated
mutation rate in these repetitive contexts is likely to be orders of magnitude higher
than the background MNV mutation rate originating from the combination of two
SNV events35–37.
Calculating the proportion of MNVs per biological origin. We calculated the
proportion of MNV per biological origin by comparing the observed number of
MNVs (that are not in repetitive contexts) with the expected number of MNV
under single-nucleotide mutational model.
Specifically, if we simply hypothesize most of the MNV are combination of two
single-nucleotide substitution events, we can estimate the relative probability of
MNV event per substitution pattern. For example, probability of observing a CA to
TG MNV in a single individual, single site (p(CA→ TG)) is proportional to p
(CA→ TA) p(TA→ TG)+ p(CA→ CG) p(CG→ TG), and probability of TA to
GC MNV (p(TA→GC)) is proportional to
pðTA ! GAÞ  pðGA ! GCÞ þ pðTA ! TCÞ  pðTC ! GCÞ. Former equation
involves the product of transition at CpG, while both term of the latter are product
of transversion at non-CpG, which works as a reasonable explanation of the
frequency difference of those two MNV patterns.
Using the same principle (and accounting for reference base pair frequency,
population number and global SNV mutation rate defined by 3 bp context26, we
first constructed a null model of MNV distribution. In reality, this null model does
not represent the real distribution we observe, due to biological mechanisms that
introduce MNV. Therefore, we allowed additional factor q, that denotes the
mutational event where two SNVs are introduced at the same time. For the
example of pðCA ! TGÞ, we model this probability to be proportional to
lpðTA ! GAÞ  pðGA ! GCÞ þ pðTA ! TCÞ  pðTC ! GCÞ þ qðCA ! TGÞ,
and try to estimate the q term, which corresponds to the proportion of MNVs that
are explained by non-SNV (and non-repeat) factor. Further details are explained in
the Supplementary Methods (section “Models and assumptions for calculating the
proportion of MNV per biological mechanism”).
In addition, for each of MNV pattern, we annotated the predicted major
mechanism for each MNV pattern in the following order:
1. Pol-zeta, for the patterns known as polymerase signature (GA- > TT and
GC- > AA)
2. Repeat, for the patterns whose fraction of MNVs in repeat contexts are >10%
(corresponding to two standard deviations away from the mean; AA- > TT, AT- >
TA, and TA- > AT)
3. One of Ti at CpG, Ti, Ti at CpG+ Tv, Ti+ Tv, Tv combination, based on
possible combinations of single-nucleotide mutational processes. For example, Ti at
CpG is when transition in CpG combined with another transition can occur in the
mutational processes (Supplementary Data 3).
Estimation of the global MNV rate per substitution pattern. In order to esti-
mate the global MNV mutation rate for adjacent MNVs, as well as the mutation
rate per MNV pattern, we first focused the number of one-step MNVs, assuming
that there are no recurrent mutations and therefore the allele frequency of con-
stituent SNVs are equal if and only if it originates from an MNV event in a single
generation. In this section, we will simply write one-step MNV of distance 1 bp
(i.e., adjacent) as MNV.
We then calculated the global MNV mutation rate under the Watterson
estimator model, as in Kaplanis et al.2. Specifically, we divided the number of MNV
sites by the number of SNV sites in our gnomAD data set, and scaled by the global
single-nucleotide mutation rate identified in previous research (1.2 × 10−8), which
yielded 2.94 × 10−11 per 2 bp per generation. This is roughly two-thirds of the
estimation provided by the Kaplanis et al.2 using trio data, slightly smaller
presumably due to differing filtering method. Next, In order to get the mutation
rate per 2 bp for each of the MNV patterns, we simply scaled the global MNV
mutation rate described above by the number of reference 2 bp and the coverage
difference. The full data for all the 78 patterns are shown in Supplementary Data 3.
Further details are explained in the Supplementary Methods (section “Models and
assumptions for estimation of the global MNV rate per substitution pattern”).
Functional enrichment. Thirteen functional annotations were collected from
Finucane et al.41 as a bed file (which originates from database, such as ENCODE,
Roadmap61 and UCSC genome browser62.) For the methylation data, we collected
the genome methylation level from ENCODE, and calculated the fraction of
methylated CpG out of all the CpGs in the region, and ordered by the fraction
(Supplementary Table 4).
MNV density calculation was performed under the null hypothesis that the
number of MNV of type WX→YZ we observe in an arbitrary genomic interval is
proportional to the number of WX in the interval. Specifically, the MNV density of
WX→YZ in interval I is defined as
DðWX ! YZjIÞ ¼ NðWX!YZjIÞNðWXjIÞ , where N(WX→YZ|I) is the number of MNVs of
WX→YZ, and N(WX|I) is the number of WX in the reference genome we observe
in that specific genomic interval. We then normalized the density by dividing by D
(WX→YZ|I= whole genome) for scaling purpose (i.e., D(WX→YZ|I)= k means
that the probability of observing a mutation of WX→YZ given a sequence context
of WX is k times higher in genomic functional category I than the overall genome.)
For estimating the fraction of MNVs per origin, we took a thresholding
approach and defined four MNVs (CA- > TG, AC- > GT, CC- > TT, and GA- > AG)
as CpG signal, two (GC- > AA, GA- > TT) as pol-zeta, three as repeat (AA- > TT,
TA- > AT, AT- > TA) and six transversion (TA- > GC, CG- > AT, AT- > CG, CG- >
GC, GC- > CG, CG- > AC) signal (and left all the other 78-(4+ 2+ 3+ 6)= 63
patterns as others, in order to highlight the strongest signals) based on the result
from Fig. 3. The fraction of MNVs per origin is then defined simply as the number
of MNVs that fall into that pattern divided by all the MNVs, in the genomic
interval. The coverage difference per interval was as small as negligible
(Supplementary Table 4).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The list of coding MNVs in gnomAD exome are available at gs://gnomad-public/release/
2.1/mnv/gnomad_mnv_coding.tsv (tab separated file). The coding MNVs consisting of
three SNVs in a single codon is available as a separate file at gs://gnomad-public/release/
2.1/mnv/gnomad_mnv_coding_3bp.tsv. The list of frame-restoring indel pairs are
available at gs://gnomad-public/release/2.1/mnv/frame_restoring_indels.tsv. The list of
all the MNVs in gnomAD genomes are available at gs://gnomad-public/release/2.1/mnv/
genome/gnomad_mnv_genome_d{i}.tsv.bgz (tab separated file, compressed. Replace {i}
(0 < i < 11) with the distance between two SNVs of MNV.), or gs://gnomad-public/
release/2.1/mnv/genome/gnomad_mnv_genome_d{i}.ht (hail table. Replace {i} (0 < i <
11) with the distance between two SNVs of MNV.). Explanations for each column in
each file can be found at gs://gnomad-public/release/2.1/mnv/mnv_readme.md. All the
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files above are also available at the download page of the gnomAD browser (https://
gnomad.broadinstitute.org/downloads).
Code availability
The code used in the study is available at https://github.com/macarthur-lab/
gnomad_mnv.
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